AU2002257497B2 - Derivatives of exendin - Google Patents

Derivatives of exendin Download PDF

Info

Publication number
AU2002257497B2
AU2002257497B2 AU2002257497A AU2002257497A AU2002257497B2 AU 2002257497 B2 AU2002257497 B2 AU 2002257497B2 AU 2002257497 A AU2002257497 A AU 2002257497A AU 2002257497 A AU2002257497 A AU 2002257497A AU 2002257497 B2 AU2002257497 B2 AU 2002257497B2
Authority
AU
Australia
Prior art keywords
exendin
lys
peptide
arg
fmoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002257497A
Other languages
English (en)
Other versions
AU2002257497A1 (en
Inventor
Chunjuan Shen
Yukun Sun
Dengxi Wu
Gang Yu
Shaoling Zhao
Jiaxiang Zhou
Zhiyong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Benemae Pharmaceutical Corp
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Publication of AU2002257497A1 publication Critical patent/AU2002257497A1/en
Application granted granted Critical
Publication of AU2002257497B2 publication Critical patent/AU2002257497B2/en
Assigned to SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION reassignment SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION Request to Amend Deed and Register Assignors: SHANGHAI HUAYI BIO LAB
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002257497A 2001-05-10 2002-05-08 Derivatives of exendin Expired AU2002257497B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB011128569A CN1162446C (zh) 2001-05-10 2001-05-10 促胰岛素分泌肽衍生物
CN01112856.9 2001-05-10
PCT/CN2002/000316 WO2002090388A1 (en) 2001-05-10 2002-05-08 Derivatives of exendin

Publications (2)

Publication Number Publication Date
AU2002257497A1 AU2002257497A1 (en) 2003-05-01
AU2002257497B2 true AU2002257497B2 (en) 2007-10-11

Family

ID=4659603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002257497A Expired AU2002257497B2 (en) 2001-05-10 2002-05-08 Derivatives of exendin

Country Status (9)

Country Link
US (1) US7329646B2 (enExample)
EP (2) EP1386930A4 (enExample)
JP (1) JP4287153B2 (enExample)
KR (1) KR100902208B1 (enExample)
CN (1) CN1162446C (enExample)
AU (1) AU2002257497B2 (enExample)
BR (1) BRPI0209685B8 (enExample)
CA (1) CA2446394C (enExample)
WO (1) WO2002090388A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN100535003C (zh) * 2004-09-06 2009-09-02 上海华谊生物技术有限公司 Exendin 4的类似物
JP5107713B2 (ja) * 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
CN100429227C (zh) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
MX2008015107A (es) * 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
EP3456340B1 (en) * 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
CN101040936B (zh) * 2007-04-28 2011-10-19 大连水产学院 防治鱼类寄生虫病的复方中草药制剂
CN101215324B (zh) * 2007-12-26 2010-11-24 吉林大学 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用
KR100864584B1 (ko) * 2008-02-25 2008-10-24 성균관대학교산학협력단 비오틴으로 수식된 엑센딘 유도체, 이의 제조방법 및 이의용도
CN101463078B (zh) * 2009-01-12 2011-07-27 华东师范大学 一种Exendin-4衍生物及其固相化学合成
CN101665799A (zh) * 2009-06-29 2010-03-10 华东师范大学 一种Exendin-4衍生物的重组制备方法和应用
WO2011063549A1 (zh) * 2009-11-26 2011-06-03 Wu Xiaoyan 长效exendin4的类似物
CN102397558B (zh) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
CN102532301B (zh) * 2010-12-31 2014-09-03 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
CN106928341B (zh) * 2011-03-30 2021-06-01 上海仁会生物制药股份有限公司 定点单取代聚乙二醇化Exendin类似物及其制备方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041561A1 (en) * 1999-12-07 2001-06-14 Lee Yong Hwa A bathtub for a pet dog

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DK144093D0 (enExample) * 1993-12-23 1993-12-23 Novo Nordisk As
US6265204B1 (en) * 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
CA2309356C (en) * 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
NZ504258A (en) * 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041561A1 (en) * 1999-12-07 2001-06-14 Lee Yong Hwa A bathtub for a pet dog

Also Published As

Publication number Publication date
CA2446394A1 (en) 2002-11-14
EP2223938B1 (en) 2013-07-10
US20040142866A1 (en) 2004-07-22
US7329646B2 (en) 2008-02-12
WO2002090388A1 (en) 2002-11-14
EP2223938A1 (en) 2010-09-01
BRPI0209685B8 (pt) 2021-05-25
JP2005502595A (ja) 2005-01-27
EP1386930A4 (en) 2005-09-07
KR20030094386A (ko) 2003-12-11
BR0209685A (pt) 2004-07-13
EP1386930A1 (en) 2004-02-04
CN1363559A (zh) 2002-08-14
JP4287153B2 (ja) 2009-07-01
KR100902208B1 (ko) 2009-06-11
BRPI0209685B1 (pt) 2016-03-01
CA2446394C (en) 2016-08-16
CN1162446C (zh) 2004-08-18

Similar Documents

Publication Publication Date Title
EP2223938B1 (en) Derivatives of exendin
JP4716641B2 (ja) グルカゴン様ペプチド−１類似体
KR101087859B1 (ko) 인슐린친화성 펩타이드 합성법
EP1575490A2 (en) Modified glucagon-like peptide-1 analogs
CA2468100A1 (en) Insulin molecule having protracted time action
JP2010509248A (ja) Ｐｅｇ修飾エキセンジンまたはエキセンジン類似体およびそれらの組成物および使用
CN111566123A (zh) 胰高血糖素样肽的制备方法
CN1976948A (zh) 修饰的Exendins及其应用
CN102718868A (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
CN101255191A (zh) 微波促进固相合成胰高血糖素样肽-1(glp-1)类似物及其应用
AU2007220775A1 (en) Selective VPAC2 receptor peptide agonists
CN119039417B (zh) 多肽化合物及其应用
US20210395328A1 (en) Method for modification of polypetide and uses
KR100997835B1 (ko) 엑센딘 4 폴리펩타이드 단편
EP2986315A2 (en) Chemically and thermodynamically stable insulin analogues and improved methods for their production
EP3888667B1 (en) Glucagon analog and methods of use thereof
CN117143221A (zh) 一种glp-1r、gipr和gcgr三重激动剂化合物
CN112218876B (zh) 进行封端的利西拉来合成
US20230044268A1 (en) An improved process for preparation of liraglutide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired